|
1
|
Ploeg M, Aben KK and Kiemeney LA: The
present and future burden of urinary bladder cancer in the world.
World J Urol. 27:289–293. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Salem HK and Mahfouz S: Changing patterns
(age, incidence, and pathologic types) of schistosoma-associated
bladder cancer in Egypt in the past decade. Urology. 79:379–383.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mokhtar N, Gouda I and Adel I: Cancer
pathology registry 2003–2004 and time trend analysis NCI. El Sheraa
Press; Cairo: 2007
|
|
4
|
Cheng L, Montironi R, Davidson DD and
Lopez-Beltran A: Staging and reporting of urothelial carcinoma of
the urinary bladder. Mod Pathol. 22(Suppl 2): 70–95. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Als AB, Dyrskjøt L, von der Maase H, et
al: Emmprin and survivin predict response and survival following
cisplatin-containing chemotherapy in patients with advanced bladder
cancer. Clin Cancer Res. 13:4407–4414. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yan L, Zucker S and Toole BP: Roles of the
multifunctional glycoprotein, emmprin (basigin; CD147), in tumour
progression. Thromb Haemost. 93:199–204. 2005.PubMed/NCBI
|
|
7
|
Han ZD, Bi XC, Qin WJ, et al: CD147
expression indicates unfavourable prognosis in prostate cancer.
Pathol Oncol Res. 15:369–374. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang Z, Huang H, Li H, et al: EMMPRIN
expression in tongue squamous cell carcinoma. J Oral Pathol Med.
38:518–523. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu W, Liu J, Xiong X, et al: Expression of
MMP9 and CD147 in invasive squamous cell carcinoma of the uterine
cervix and their implication. Pathol Res Pract. 205:709–715. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhu S, Li Y, Mi L, et al: Clinical impact
of HAb18G/CD147 expression in esophageal squamous cell carcinoma.
Dig Dis Sci. 56:3569–3576. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hashimoto Y, Skacel M and Adams JC: Roles
of fascin in human carcinoma motility and signaling: prospects for
a novel biomarker? Int J Biochem Cell Biol. 37:1787–1804. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang H, Xu L, Xiao D, et al: Fascin is a
potential biomarker for early-stage oesophageal squamous cell
carcinoma. J Clin Pathol. 59:958–964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Darnel AD, Behmoaram E, Vollmer RT, et al:
Fascin regulates prostate cancer cell invasion and is associated
with metastasis and biochemical failure in prostate cancer. Clin
Cancer Res. 15:1376–1383. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lin CK, Chao TK, Yu CP, et al: The
expression of six biomarkers in the four most common ovarian
cancers: correlation with clinicopathological parameters. APMIS.
117:162–175. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhong WD, Chen QB, Ye YK, et al:
Extracellular matrix metalloproteinase inducer expression has an
impact on survival in human bladder cancer. Cancer Epidemiol.
34:478–482. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Han ZD, He HC, Bi XC, et al: Expression
and clinical significance of CD147 in genitourinary carcinomas. J
Surg Res. 160:260–267. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Afonso J, Longatto-Filho A, Baltazar F, et
al: CD147 overexpression allows an accurate discrimination of
bladder cancer patients’ prognosis. Eur J Surg Oncol. 37:811–817.
2011.PubMed/NCBI
|
|
18
|
Wittschieber D, Stenzinger A, Klauschen F,
et al: Decreased RECK and increased EMMPRIN expression in
urothelial carcinoma of the bladder are associated with tumor
aggressiveness. Pathobiology. 78:123–131. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Karasavvidou F, Barbanis S, Pappa D, et
al: Fascin determination in urothelial carcinomas of the urinary
bladder: a marker of invasiveness. Arch Pathol Lab Med.
132:1912–1915. 2008.PubMed/NCBI
|
|
20
|
Bi J, Chen X, Zhang Y, et al: Fascin is a
predictor for invasiveness and recurrence of urothelial carcinoma
of bladder. Urol Oncol. 30:688–694. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
McKnight R, Cohen C and Siddiqui MT:
Fascin stain as a potential marker of invasiveness in carcinomas of
the urinary bladder: a retrospective study with biopsy and cytology
correlation. Diagn Cytopathol. 39:635–640. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Xie JJ, Xu LY, Zhang HH, et al: Role of
fascin in the proliferation and invasiveness of esophageal
carcinoma cells. Biochem Biophys Res Commun. 337:355–362. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Eble JN, Sauter G, Epstein JI and
Sesterhenn IA: World Health Organization classification of tumors.
Pathology and genetics of tumors of the urinary system and male
genital organs. IARC Press; Lyon: pp. 90–109. 2004
|
|
24
|
Takikita M, Hu N, Shou JZ, et al: Fascin
and CK4 as biomarkers for esophageal squamous cell carcinoma.
Anticancer Res. 31:945–952. 2011.PubMed/NCBI
|
|
25
|
Jayo A and Parsons M: Fascin: a key
regulator of cytoskeletal dynamics. Int J Biochem Cell Biology.
42:1614–1617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tong GX, Yee H, Chiriboga L, et al:
Fascin-1 expression in papillary and invasive urothelial carcinomas
of the urinary bladder. Hum Pathol. 36:741–746. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Blaveri E, Simko JP, Korkola JE, et al:
Bladder cancer outcome and subtype classification by gene
expression. Clin Cancer Res. 11:4044–4055. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Shokeir AA: Squamous cell carcinoma of the
bladder: pathology, diagnosis and treatment. BJU int. 93:216–220.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tsai WC, Sheu LF, Nieh S, et al:
Association of EMMPRIN and fascin expression in renal cell
carcinoma: correlation with clinicopathological parameters. World J
Urol. 25:73–80. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jung EJ, Lee JH, Min BW, et al:
Clinicopathologic significance of fascin, extracellular matrix
metalloproteinase inducer, and ezrin expressions in colorectal
adenocarcinoma. Indian J Pathol Microbiol. 54:32–36. 2011.
View Article : Google Scholar
|
